Palvella Therapeutics, Inc. PVLA

Competitive advantage analysis · healthcare

Corporate Default
Overall moat score
49/100
Developing

Ranked against 712 peers in Biotechnology

About Palvella Therapeutics, Inc.

Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN 3.9% rapamycin anhydrous gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous … Full PVLA analysis →

Key strengths

  • Margins Stable Across Cycles Operating margin volatility is low (stability score 0.87), demonstrating pricing resilience across cycles.

Key risks

  • ROIC Below WACC or Peers ROIC at 22.7th percentile suggests inefficient capital deployment.
  • Scale Without Profitability Despite scale, profitability lags peers (score 0.00), suggesting limited competitive advantage.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Strong
87
Premium

Signals, strengths and risks for Pricing Power

Premium

Signals, strengths and risks for Cost Advantage

Premium

Signals, strengths and risks for Customer Stickiness

Premium

Signals, strengths and risks for Capital Efficiency

Premium

Signals, strengths and risks for Resilience

Premium

Signals, strengths and risks for Scale & Market Position

Where PVLA ranks in Biotechnology

Palvella Therapeutics, Inc. ranks #250 of 713 scored companies in Biotechnology by moat score — the top 35%. The widest moat in the group is Royalty Pharma plc (RPRX) at 85/100.

# Company Moat score Rating
246 Adicet Bio, Inc. ACET 50/100 Developing
247 Cybin Inc. CYBN 50/100 Developing
248 MediWound Ltd. MDWD 49/100 Developing
249 Agios Pharmaceuticals, Inc. AGIO 49/100 Developing
250 Palvella Therapeutics, Inc. PVLA 49/100 Developing
251 Syndax Pharmaceuticals, Inc. SNDX 49/100 Developing
252 Coya Therapeutics, Inc. COYA 49/100 Developing
253 Immuron Limited IMRN 49/100 Developing
254 Editas Medicine, Inc. EDIT 49/100 Developing

See every Biotech / Pre-Revenue company ranked by moat score →

How PVLA scores on the Corporate Default defenses

Pricing Power

Score 87 · 20% of the moat score

Pricing power is the ability to raise prices without losing volume.

Cost Advantage

Not measurable · 15% of the moat score

A cost advantage means delivering the same product for structurally less — better purchasing, denser distribution, a more automated process.

Customer Stickiness

Score 66 · 15% of the moat score

Stickiness is what makes revenue repeat without being re-won every year.

Capital Efficiency

Score 26 · 18% of the moat score

Capital efficiency asks what the company earns on the money tied up in the business.

Resilience

Score 49 · 17% of the moat score

Resilience is the capacity to get through a bad year on its own terms — enough liquidity, enough interest cover, and enough cash generation to avoid a rescue financing or a forced sale.

Scale & Market Position

Score 37 · 15% of the moat score

Scale matters only when it converts into economics.

How each Corporate Default defense is measured, in full →

Understanding PVLA's moat

What is Palvella Therapeutics, Inc.'s moat score?

Palvella Therapeutics, Inc. (PVLA) scores 49 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as developing. It ranks #250 of 713 scored companies in Biotechnology, the top 35%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 712 companies in Biotechnology. Its strongest defense is Pricing Power (87/100) and its weakest is Capital Efficiency (26/100).

How does Palvella Therapeutics, Inc. compare with other Biotechnology companies?

Palvella Therapeutics, Inc. ranks #250 of 713 scored companies in Biotechnology by moat score. The widest moat in Biotechnology is Royalty Pharma plc (RPRX) at 85/100. The companies ranked closest are Agios Pharmaceuticals, Inc. (AGIO) at 49 just above it and Syndax Pharmaceuticals, Inc. (SNDX) at 49 just below it.

How is the moat score calculated?

Each company is scored with an industry-specific template — Corporate Default in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 712 companies in Biotechnology. The defenses are then weighted to produce the overall score out of 100.

Why is Palvella Therapeutics, Inc. scored with the Corporate Default template?

Most public companies sell a product or a service at a margin, so the moat question is whether that margin survives contact with competitors. The Corporate template scores the six defenses that show up in a general operating company's financial signature: whether it can hold price, produce more cheaply than rivals, keep its customers, earn a return above its cost of capital, withstand a downturn, and turn size into economics.

Which competitive defenses are measured for Palvella Therapeutics, Inc.?

The Corporate Default template measures 6 defenses, and PVLA scores: Pricing Power (87), Cost Advantage (not measurable), Customer Stickiness (66), Capital Efficiency (26), Resilience (49), Scale & Market Position (37). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

Send Feedback
Please select a category.
0/1000